** BofA Global Research double upgrades Demant DEMANT.CO to "buy" from "underperform", citing traction for its newly launched hearing device Oticon Zeal and a bright market outlook

** Says Zeal "adds volume to the bull case" and together with a new platform launch and a more dynamic market offsets risks tied to Costco COST.O

** Notes hearing aid sector could see earnings upgrades if second-quarter growth holds near the about 5% seen in the first quarter, making Demant's FY 2026 outlook "look conservative"

** Adds that an upcoming broader platform launch this summer could help the Danish hearing aid maker regain momentum across its existing portfolio after several challenging years

** Sees the stock "appealing" at roughly 11 times 2027 estimated EBITDA, noting short-squeeze potential

** 13 out of the 21 analysts covering the stock rate it "strong buy"/"buy", seven "hold", one "sell" - LSEG data